Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Broadfin Capital and Bridger Management Think SeaSpine Holdings Corp (SPNE) Is Oversold

However, there are some industry characteristics that might inhibit the company’s rapid growth. According to iData Research, the expected annual growth for the Orthobiologics market from 2014 to 2021 is only 3.4%, and for the spinal Fusion Hardware market the growth figure is even lower at just 0.7%. Thus it is not surprising that since its IPO on June 19, SeaSpine Holdings Corp (NASDAQ:SPNE)’s stock has fallen by about 15%. However, Broadfin Capital and Bridger Management’s latest move might suggest that this presents a great entry point, especially considering that the company currently only has 18% market share in the orthobiologics segment.

Roberto Mignone
Roberto Mignone
Bridger Management

Hedge funds have been enthusiastic about Integra Lifesciences Holdings Corp (NASDAQ:IART), especially during the first quarter when SeaSpine Holdings Corp (NASDAQ:SPNE) was part of its business. Among the funds that we track, 13 had an aggregate investment of $73.78 million in Integra Lifesciences Holdings Corp (NASDAQ:IART) at the end of March, compared to seven firms with $33.43 million in shares at the end of the previous quarter. The largest investors of Integra Lifesciences among the funds we track, as of March 31, were Ken Fisher‘s Fisher Asset Management and Paul Tudor Jones’ Tudor Investment Corp, with respective holdings amounting to 520,200 shares valued at $32.07 million and 200,000 shares valued at $12.33 million.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.